Helmut Paul

Paul, H., Berg, V., Gangadharan, B.M., Bowen, J., LeBeau, P., Blatny, J., Male, C., Radulescu, V., Diaz, R., Mancuso, M.E., Brown, D.L., Reipert, B.M. (2022): Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication. Blood Advances, Epub ahead of print.

Schweiger, H., Rejtö, J., Hofbauer, C.J., Berg, V., Allacher, P., Zwiauer, K., Feistritzer, C., Schuster, G., Ay, C., Reipert, B.M., Pabinger, I. (2022): Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Advances, 6(3): 946-958.

Reipert, B.M., Gangadharan, B., Hofbauer, C.J., Berg, V., Schweiger, H., Bowen, J., Blatny, J., Fijnvandraat, K., Mullins, E.S., Klintman, J., Male, C., McGuinn, C., Meeks, S.L., Radulescu, V.C., Ragni, M.V., Recht, M., Shapiro, A.D., Staber, J.M., Yaish, H.M., Santagostino, E., Brown, D.L. (2020): The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Advances, 4(22): 5785–5796.

Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.